The development of a novel bispecific ADC targeting HER2 and HER3, for example, has demonstrated potent therapeutic efficacy against BC, indicating a promising strategy for overcoming limitations associated with single-target approaches [7]. This evidence concerns the gene ERBB2 and breast cancer.